Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.
Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.
<iframe src="https://statesidedaily.com/embed/cluster/ebdb44f6bccd56c169723676ffa14f41b8c77753" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio"></iframe>